Usage Examples
- We cannot ship that lot until the GMP batch record review is closed.
- The site is GMP-ready for commercial supply; the CMO's second line is not.
- Our GMP retention clock runs from the expiration date, not the manufacturing date.
What is GMP (Good Manufacturing Practice)?
GMP is the minimum standard for the methods, facilities, and controls used to manufacture a drug, enforced through adulteration: a drug made outside GMP is legally adulterated regardless of whether it passes its release tests.
GMP exists because quality cannot be tested into a finished drug. Release testing examines a few units from a batch of millions, so a contaminated or sub-potent lot can still pass. GMP therefore regulates the production system itself, the methods, facilities and controls used to make the drug, and treats a failure of that system as an adulteration of the product.
GMP covers the manufacture, processing, packing and holding of a drug: the quality unit's authority, written production procedures, batch records, investigations and record retention. GMP does not cover how a molecule was discovered, how it performed in trials, or how it is promoted. GMP for finished pharmaceuticals sits in 21 CFR Parts 210 and 211; finished medical devices are covered by a separate quality-system regulation.
GMP is applied, day to day, through the quality unit's release decision. Every production and control record is reviewed against approved written procedures before a batch is released or distributed, and any unexplained discrepancy or specification failure triggers a written investigation that must reach other batches and other products. GMP compliance is then verified by inspection, where the investigation file carries more weight than the procedure binder.
Not to be confused with
- cGMP
- cGMP is not a stricter tier above GMP. The FDA regulations are formally titled current good manufacturing practice, so cGMP is the rule set's own name and GMP is the shorthand for it; no inspection finding turns on which word you used.
- Validation
- validation is one activity performed to demonstrate that a process, method or system does what it is supposed to do. GMP is the standard that makes validation necessary. A fully validated process inside a site without a functioning quality unit is still non-compliant.
- Batch record
- the batch record is the evidence GMP requires; GMP is the rule set that defines what must be in it, who reviews it, and how long it is kept. A complete batch record does not by itself establish GMP compliance, because compliance also turns on what the review found.
- 21 CFR Part 820
- Part 820 carries the quality-system requirements for finished medical devices; Parts 210 and 211 carry them for finished drugs. A combination product can be in scope for both, but a drug GMP inspection never covers Part 820.
GMP obligations attach to the record holder, not the equipment vendor or the contract manufacturer alone. These are the anchors for finished pharmaceuticals.
What you must do
- 1Establish a quality control unit with the authority to approve or reject all components, containers, closures, in-process materials, packaging, labeling and finished drug products, and to review production records for errors21 CFR 211.22(a)
- 2Have the quality control unit review and approve all production and control records, including packaging and labeling, against established approved written procedures before a batch is released or distributed21 CFR 211.192
- 3Thoroughly investigate any unexplained discrepancy, including theoretical yield outside the established range, or any failure to meet specification, whether or not the batch has already been distributed21 CFR 211.192
- 4Extend that investigation to other batches of the same drug product and to other drug products that may have been associated with the failure, and make a written record including conclusions and follow-up21 CFR 211.192
- 5Retain every production, control and distribution record associated with a batch for at least 1 year after the batch expiration date, or 3 years after distribution for OTC products exempt from expiration dating21 CFR 211.180(a)
- 6For sterile medicinal products supplied in the EU, manufacture under EudraLex Volume 4 Annex 1, fully applicable since 25 August 2024EU GMP Annex 1
Common mistakes
Closing an investigation at the batch that failed
21 CFR 211.192 requires the investigation to extend to other batches of the same drug product and to other drug products that may have been associated with the failure. Scoping to the single lot leaves that explicit extension requirement unmet, and it is what turns one rejected batch into a field action across everything made on the same line.
Running the record retention clock from the manufacturing date
21 CFR 211.180(a) ties retention to the expiration date of the batch, not the date it was made. A record purged on a manufacture-date schedule can disappear while the product is still on the market, leaving no way to reconstruct the batch during a complaint, recall or inspection request.
Treating a passing release test as proof of GMP compliance
under 21 CFR 210.1(b), failure to comply with the CGMP regulations renders the drug adulterated and exposes the responsible person as well as the product to regulatory action, independent of any test result. Companies that manage GMP as a testing standard find the gap during an inspection, when the finding attaches to the system rather than the sample.
When This Matters
- We cannot ship that lot until the GMP batch record review is closed.
- The site is GMP-ready for commercial supply; the CMO's second line is not.
- Our GMP retention clock runs from the expiration date, not the manufacturing date.
Frequently Asked Questions
GMP and cGMP name the same body of rules. The FDA regulations are formally titled current good manufacturing practice (21 CFR 210.1(a)), so cGMP is the regulation's own name and GMP is the everyday shorthand. In practice the c signals that expectations track current technology and industry practice rather than a frozen historical minimum.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
